Sunovion Pharmaceuticals Inc. to Present New Data on Latuda® (lurasidone HCl) at the 167th Annual Meeting of the ... Sunovion Pharmaceuticals Inc. will present 20 research posters on Latuda® , an atypical antipsychotic agent indicated for the treatment of adult patients with major depressive episodes associated with bipolar I disorder both as monotherapy and as adjunctive therapy with lithium or valproate, and for the treatment of adult patients with schizophrenia, at the 167th Annual Meeting of the American ...
May 1, 2014 - Business Wire via Yahoo! Finance